Research Article Details
| Article ID: | A06959 |
| PMID: | 32686456 |
| Source: | Rev Esp Enferm Dig |
| Title: | What may GLP1 receptor agonists contribute to the treatment of patients with non-alcoholic fatty liver disease? |
| Abstract: | Non-alcoholic fatty liver disease (NAFLD) poses a challenge to health services both in developed and developing countries, with a significant increase in incidence and prevalence that is related to the currently increased prevalence of obesity. Besides an acknowledged higher risk for advanced liver disease (cirrhosis, hepatocellular carcinoma), morbidity and mortality from cardiovascular disease both increase in people with NAFLD. As a matter of fact, NAFLD is a cardiovascular risk factor. |
| DOI: | 10.17235/reed.2020.7148/2020 |
| Strategy ID | Therapy Strategy | Synonyms | Therapy Targets | Therapy Drugs |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I14 | 9970 | Obesity | An overnutrition that is characterized by excess body fat, traditionally defined as an elevated ratio of weight to height (specifically 30 kilograms per meter squared), has_material_basis_in a multifactorial etiology related to excess nutrition intake, decreased caloric utilization, and genetic susceptibility, and possibly medications and certain disorders of metabolism, endocrine function, and mental illness. https://en.wikipedia.org/wiki/Obesity | disease of metabolism/acquired metabolic disease/ nutrition disease/overnutrition | Details |